Search

Your search keyword '"Chen, Minhu"' showing total 603 results
Start Over Author "Chen, Minhu" Search Limiters Full Text
603 results on '"Chen, Minhu"'

4. Diet-omics in the Study of Urban and Rural Crohn disease Evolution (SOURCE) cohort

Author

Braun, Tzipi, Feng, Rui, Amir, Amnon, Levhar, Nina, Shacham, Hila, Mao, Ren, Hadar, Rotem, Toren, Itamar, Algavi, Yadid, Abu-Saad, Kathleen, Zhuo, Shuoyu, Efroni, Gilat, Malik, Alona, Picard, Orit, Yavzori, Miri, Agranovich, Bella, Liu, Ta-Chiang, Stappenbeck, Thaddeus S., Denson, Lee, Kalter-Leibovici, Ofra, Gottlieb, Eyal, Borenstein, Elhanan, Elinav, Eran, Chen, Minhu, Ben-Horin, Shomron, and Haberman, Yael

Published
2024
Full Text
View/download PDF

10. Blocking Dectin-1 prevents colorectal tumorigenesis by suppressing prostaglandin E2 production in myeloid-derived suppressor cells and enhancing IL-22 binding protein expression

Author

Tang, Ce, Sun, Haiyang, Kadoki, Motohiko, Han, Wei, Ye, Xiaoqi, Makusheva, Yulia, Deng, Jianping, Feng, Bingbing, Qiu, Ding, Tan, Ying, Wang, Xinying, Guo, Zehao, Huang, Chanyan, Peng, Sui, Chen, Minhu, Adachi, Yoshiyuki, Ohno, Naohito, Trombetta, Sergio, and Iwakura, Yoichiro

Published
2023
Full Text
View/download PDF

13. Asian-Pacific consensus on small intestinal bacterial overgrowth in gastrointestinal disorders: An initiative of the Indian Neurogastroenterology and Motility Association

Author

Ghoshal, Uday C., Sachdeva, Sanjeev, Ghoshal, Ujjala, Misra, Asha, Puri, Amarender Singh, Pratap, Nitesh, Shah, Ayesha, Rahman, M. Masudur, Gwee, Kok Ann, Tan, Victoria P Y, Ahmed, Tahmeed, Lee, Yeong Yeh, Ramakrishna, B S, Talukdar, Rupjyoti, Rana, S V, Sinha, Saroj K, Chen, Minhu, Kim, Nayoung, and Holtmann, Gerald

Published
2022
Full Text
View/download PDF

14. CT-based radiomics signature of visceral adipose tissue for prediction of disease progression in patients with Crohn's disease: a multicentre cohort study

Author

Li, Xuehua, Zhang, Naiwen, Hu, Cicong, Lin, Yuqin, Li, Jiaqiang, Li, Zhoulei, Cui, Enming, Shi, Li, Zhuang, Xiaozhao, Li, Jianpeng, Lu, Jiahang, Wang, Yangdi, Liu, Renyi, Yuan, Chenglang, Lin, Haiwei, He, Jinshen, Ke, Dongping, Tang, Shanshan, Zou, Yujian, He, Bo, Sun, Canhui, Chen, Minhu, Huang, Bingsheng, Mao, Ren, and Feng, Shi-Ting

Published
2023
Full Text
View/download PDF

15. Corticosteroids and Mesalamine Versus Corticosteroids for Acute Severe Ulcerative Colitis: A Randomized Controlled Trial

Author

Ben-Horin, Shomron, Har-Noy, Ofir, Katsanos, Konstantinos H., Roblin, Xavier, Chen, Minhu, Gao, Xiang, Schwartz, Doron, Cheon, Jae Hee, Cesarini, Monica, Bojic, Daniela, Protic, Marijana, Theodoropoulou, Angeliki, Abu-Kaf, Heba, Engel, Tal, Tang, Jian, Veyrard, Pauline, Lin, Xiaoqing, Mao, Ren, Christodoulou, Dimitrios, Karmiris, Konstantinos, and Knezevic-Ivanovski, Tamara

Published
2022
Full Text
View/download PDF

16. Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction

Author

Zhou, Youlian, Xu, Zhenjiang Zech, He, Yan, Yang, Yunsheng, Liu, Le, Lin, Qianyun, Nie, Yuqiang, Li, Mingsong, Zhi, Fachao, Liu, Side, Amir, Amnon, González, Antonio, Tripathi, Anupriya, Chen, Minhu, Wu, Gary D, Knight, Rob, Zhou, Hongwei, and Chen, Ye

Subjects
Microbiology, Biological Sciences, Biomedical and Clinical Sciences, Crohn's Disease, Inflammatory Bowel Disease, Genetics, Autoimmune Disease, Digestive Diseases, Oral and gastrointestinal, gut microbiota, infliximab treatment, disease activity, inflammatory bowel disease
Abstract

Gut microbiota dysbiosis contributes to the onset and perpetuation of inflammatory bowel disease (IBD). Given that gut microbiotas vary across geography and ethnicity, it remains obscure whether any universal microbial signatures for IBD diagnosis and prognosis evaluation exist irrespective of populations. Here we profiled the fecal microbiota of a series of Chinese IBD patients and combined them with two Western IBD cohorts, PRISM and RISK, for meta-analyses. We found that the gut microbial alteration patterns in IBD are similar among Chinese and Westerners. Our prediction model based on gut microbiome for IBD diagnosis is robust across the cohorts, which showed 87.5% and 79.1% prediction accuracy in Crohn's disease (CD) and ulcerative colitis (UC) patients, respectively. A relative increase in the levels of Actinobacteria and Proteobacteria (Enterobacteriaceae) and a relative decrease in the levels of Firmicutes (Clostridiales) were strongly correlated with IBD severity (P < 0.05). Additionally, restoration of gut microbiota diversity and a significant increase in Clostridiales relative abundance were found in patients responding to infliximab (IFX [Remicade]) treatment compared to those in relapse. Moreover, certain microbes, mainly Clostridiales, predicted the treatment effectiveness with 86.5% accuracy alone and 93.8% accuracy in combination with calprotectin levels and Crohn's disease activity index (CDAI). Taking the results together, we conclude that gut microbiota can offer a set of universal biomarkers for diagnosis, disease activity evaluation, and infliximab treatment response prediction in IBD. IMPORTANCE In the present report, we show that the human fecal microbiota contains promising and universal biomarkers for the noninvasive evaluation of inflammatory bowel disease severity and IFX treatment efficacy, emphasizing the potential ability to mine the gut microbiota as a modality to stratify IBD patients and apply personalized therapy for optimal outcomes.

Published
2018

18. Microbial assimilatory sulfate reduction-mediated H2S: an overlooked role in Crohn's disease development.

Author

Luo, Wanrong, Zhao, Min, Dwidar, Mohammed, Gao, Yang, Xiang, Liyuan, Wu, Xueting, Medema, Marnix H., Xu, Shu, Li, Xiaozhi, Schäfer, Hendrik, Chen, Minhu, Feng, Rui, and Zhu, Yijun

Subjects
CROHN'S disease, INFLAMMATORY bowel diseases, SULFUR metabolism, ESCHERICHIA coli, FOOD additives, GUT microbiome, SULFATES
Abstract

Background: H2S imbalances in the intestinal tract trigger Crohn's disease (CD), a chronic inflammatory gastrointestinal disorder characterized by microbiota dysbiosis and barrier dysfunction. However, a comprehensive understanding of H2S generation in the gut, and the contributions of both microbiota and host to systemic H2S levels in CD, remain to be elucidated. This investigation aimed to enhance comprehension regarding the sulfidogenic potential of both the human host and the gut microbiota. Results: Our analysis of a treatment-naive CD cohorts' fecal metagenomic and biopsy metatranscriptomic data revealed reduced expression of host endogenous H2S generation genes alongside increased abundance of microbial exogenous H2S production genes in correlation with CD. While prior studies focused on microbial H2S production via dissimilatory sulfite reductases, our metagenomic analysis suggests the assimilatory sulfate reduction (ASR) pathway is a more significant contributor in the human gut, given its high prevalence and abundance. Subsequently, we validated our hypothesis experimentally by generating ASR-deficient E. coli mutants ∆cysJ and ∆cysM through the deletion of sulfite reductase and L-cysteine synthase genes. This alteration significantly affected bacterial sulfidogenic capacity, colon epithelial cell viability, and colonic mucin sulfation, ultimately leading to colitis in murine model. Further study revealed that gut microbiota degrade sulfopolysaccharides and assimilate sulfate to produce H2S via the ASR pathway, highlighting the role of sulfopolysaccharides in colitis and cautioning against their use as food additives. Conclusions: Our study significantly advances understanding of microbial sulfur metabolism in the human gut, elucidating the complex interplay between diet, gut microbiota, and host sulfur metabolism. We highlight the microbial ASR pathway as an overlooked endogenous H2S producer and a potential therapeutic target for managing CD. Dka3P5uGJeBhH66pkNJcog Video Abstract [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Pharmacokinetics, Safety, and Tolerability of Tenapanor in Healthy Chinese and Caucasian Volunteers: A Randomized, Open-Label, Single-Center, Placebo-Controlled Phase 1 Study

Author

Yuan, Gang, primary, Chen, Yili, additional, Li, Li, additional, Wang, Xin, additional, Wei, Gang, additional, Zeng, Jiawei, additional, Hui, Ai-Min, additional, Jiang, Yueyun, additional, Zhao, Han, additional, Diao, Lei, additional, Zhou, Yongchun, additional, Xiao, Yinglian, additional, and Chen, Minhu, additional

Published
2024
Full Text
View/download PDF

28. Risk Perception, Acceptance, and Trust of Using Artificial Intelligence in Gastroenterology Practice: Survey from the Asia Pacific Region (Preprint)

Author

Goh, Wilson W.B., primary, Chia, Kendrick Y.A., additional, Cheung, Max F.K., additional, Kee, Kalya M., additional, Lwin, May O., additional, Schulz, Peter J., additional, Chen, Minhu, additional, Wu, Kaichun, additional, Ng, Simon S.M., additional, Lui, Rashid, additional, Ang, Tiing Leong, additional, Yeoh, Khay Guan, additional, Chiu, Han-mo, additional, Wu, Deng-chyang, additional, and Sung, Joseph J.Y., additional

Published
2023
Full Text
View/download PDF

29. Rapidly achieving clinical remission in ulcerative colitis indicates better endoscopic and histological outcomes

Author

Chen, Rirong, Tie, Yizhe, Huang, Yongle, Zhang, Xi, Zeng, Zhirong, Chen, Minhu, Li, Li, and Zhang, Shenghong

Abstract

Clinical remission (CR) is the principal short‐term treatment target in patients with ulcerative colitis (UC). However, whether rapidly achieving CR indicates better outcomes remains unclear. We aimed to explore the associations between the timing of CR and therapeutic outcomes in UC. This study included UC patients from the UNIFI trial. Week‐2 CR and time to CR were the major variables of interest. Endoscopic remission (ER) at week 52 was the primary outcome. Multivariate logistic regression was performed to evaluate the association between variables and outcomes. Week‐2 CR was associated with ER (aOR: 2.37 [95% CI: 1.28, 4.37], p= 0.006) and Histological remission (HR) (aOR: 2.87 [95% CI: 1.42, 5.72], p= 0.003) at week 52. Moreover, C‐reactive protein (CRP) remission could further stratify patients without CR and predict week‐52 outcomes. Patients with clinical activity + CRP remission (aOR: 0.49 [95% CI: 0.26, 0.93], p= 0.039) and clinical activity + CRP activity (aOR: 0.24 [95% CI: 0.11, 0.52], p< 0.001) had gradually decreased likelihood of achieving ER, when compared to those with CR. For time to CR, we found that the earlier to CR, the better endoscopic and histological outcomes patients would attain. Patients achieving CR at weeks 2, 4/8, 12/16 and >16 had gradually reduced proportions of ER (51.9% vs. 40.8% vs. 31.6% vs. 8.8%, p< 0.001) and HR (37.0% vs. 19.8% vs. 17.1% vs. 6.1%, p< 0.001) at week 52. Compared with week 2, achieving CR at weeks 4/8, 12/16 and >16 had 39%, 55% and 92% lower likelihoods of week‐52 ER, respectively. Week‐2 CR indicates better outcomes in UC patients receiving ustekinumab. Moreover, achieving CR more rapidly is associated with higher probability of ER and HR.

Published
2024
Full Text
View/download PDF

38. A Novel Nomogram Combining Mucus Barrier Index for Predicting Treatment Failures in Ulcerative Colitis

Author

Wang,Ying, Huang,Xuanzhi, Zhou,Gaoshi, Han,Jing, Xie,Zhuo, Zhang,Mudan, Li,Xiaoling, Wu,Qi-rui, Li,Li, Ye,Ziyin, Chen,Minhu, Qiu,Yun, Zhang,Shenghong, Wang,Ying, Huang,Xuanzhi, Zhou,Gaoshi, Han,Jing, Xie,Zhuo, Zhang,Mudan, Li,Xiaoling, Wu,Qi-rui, Li,Li, Ye,Ziyin, Chen,Minhu, Qiu,Yun, and Zhang,Shenghong

Abstract

Ying Wang,1,&ast; Xuanzhi Huang,1,&ast; Gaoshi Zhou,1 Jing Han,1 Zhuo Xie,1 Mudan Zhang,1 Xiaoling Li,1 Qi-rui Wu,1 Li Li,1 Ziyin Ye,2 Minhu Chen,1 Yun Qiu,1 Shenghong Zhang1 1Department of Gastroenterology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, People’s Republic of China; 2Department of Pathology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Shenghong Zhang; Yun Qiu, Department of Gastroenterology, First Affiliated Hospital of Sun Yat-sen University, 58 Zhongshan Road 2, Guangzhou Province, 510080, People’s Republic of China, Tel/Fax +86-20-87332916, Email zhshh3@mail.sysu.edu.cn; qyun@mail2.sysu.edu.cnBackground: Treatment failures (TFs) generally exist in the course of ulcerative colitis (UC), while early reliable predictors of TFs are still lacking. We aimed to generate nomograms for the prediction of TFs.Methods: In this retrospective case–control study, the endpoint was the occurrence of TFs, which included medically associated treatment failures and surgery-associated treatment failures (colectomy). Clinical features and mucus integrity evident by goblet cells (GCs) number, expression levels of MUC2 and SLC26A3 were enrolled in the univariate analysis. Nomogram performance was evaluated by discrimination and calibration.Results: We identified 256 UC patients at our center from January 2010 to June 2022. Fourteen variables for TFs and 9 for colectomy were identified by univariate analysis. Five baseline indices were incorporated into the nomogram for the prediction of TFs: area of GCs, age at diagnosis, disease duration, hemoglobin, and Mayo score. The model was presented with decent discrimination (C index of 0.822) and well calibration. In addition, the colectomy predictive nomogram was built using MUC2 intensity, age at onset, and Mayo score with a good discrimin

Published
2023

50. Additional file 3 of Oxidative stress gene expression, DNA methylation, and gut microbiota interaction trigger Crohn’s disease: a multi-omics Mendelian randomization study

Author

Xu, Shu, Li, Xiaozhi, Zhang, Shenghong, Qi, Cancan, Zhang, Zhenhua, Ma, Ruiqi, Xiang, Liyuan, Chen, Lianmin, Zhu, Yijun, Tang, Ce, Bourgonje, Arno R., Li, Miaoxin, He, Yao, Zeng, Zhirong, Hu, Shixian, Feng, Rui, and Chen, Minhu

Abstract

Additional file 3: Fig. S1. Regulatory component annotation of 665 DNA methylation (DNAm) sites. A) DNAm sites annotated with active or inactive chromatin states were enriched in different blood cell types. B) DNAm sites annotated with histone markers were enriched in different blood cell types. Reference of active chromatin states: active transcription start site (TSS)-proximal promoter states (TssA, TssAFlnk), a transcribed state at the 5′ and 3′ ends of genes showing both promoter and enhancer signatures (TxFlnk), actively transcribed states (Tx, TxWk), enhancer states (Enh, EnhG), and a state associated with zinc finger protein genes (ZNF/Rpts). Reference of inactive chromatin states: constitutive heterochromatin (Het), bivalent regulatory states (TssBiv, BivFlnk, EnhBiv), repressed polycomb states (ReprPC, ReprPCWk), and quiescent state (Quies). Reference histone marker: H3K4me1 is enriched at active and primed enhancers; H3K4me3 is a modification that is associated with transcriptionally active/poised chromatin.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results